Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation

PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions
Axial Spondyloarthritis
Interventions
DRUG

Golimumab

"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."

Trial Locations (3)

2820

Imelda Bonheiden, Bonheiden

3500

Reuma Instituut Hasselt, Hasselt

9000

Ghent University Hospital, Ghent

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

the Flanders Institute for Biotechnology

UNKNOWN

lead

University Ghent

OTHER

NCT03270501 - Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation | Biotech Hunter | Biotech Hunter